Semifluorinated Alkane Tetracycline Injection for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing injectable compositions, particularly those containing tetracycline antibiotics like doxycycline, are unstable in aqueous solutions and require reconstitution before use, making them unsuitable for ready-to-use applications, which complicates stability, shelf life, and compliance with regulatory requirements.
Innovation Solution
A stable injectable composition is developed by combining tetracycline antibiotics with semifluorinated alkanes, such as 1-perfluorohexyloctane, creating a non-aqueous vehicle that maintains the stability and efficacy of the antibiotic, allowing for ready-to-use injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If tetracycline antibiotics are formulated in aqueous solutions, then they can be administered as ready-to-use injections, but they become unstable and degrade, shortening shelf life and compromising regulatory compliance
Solution Approach 1:
The patent changes the fundamental parameter of the vehicle from aqueous to non-aqueous (semifluorinated alkane), which fundamentally alters the stability characteristics of tetracycline antibiotics. This parameter change enables the drug to remain stable in the injectable formulation without degradation, while still allowing ready-to-use administration without reconstitution.
Solution Approach 2:
The patent creates a composite injectable formulation by combining tetracycline antibiotics with semifluorinated alkanes. This composite system leverages the unique properties of both components: the antibiotic provides therapeutic effect while the semifluorinated alkane provides stability and serves as an effective vehicle, resolving the contradiction between ease of administration and stability.
2Ease of operation
If tetracycline antibiotics are stored in aqueous formulations, then they can be conveniently administered, but they require reconstitution prior to use, complicating the process and affecting shelf life
Solution Approach 1:
By changing the vehicle parameter from aqueous to non-aqueous semifluorinated alkane, the patent eliminates the need for reconstitution. The drug remains stable in the non-aqueous formulation, allowing direct administration without additional preparation steps, thus saving time and improving operational convenience.
3Ease of manufacture
If injectable compositions use aqueous vehicles, then they can be prepared and stored, but they fail to meet regulatory stability requirements and shelf life targets
Solution Approach 1:
The patent changes the vehicle parameter to non-aqueous semifluorinated alkane, which fundamentally improves the stability profile of the formulation. This enables the product to meet regulatory stability requirements and shelf life targets while maintaining ease of manufacture, as the formulation can be prepared and stored without special conditions.
4Duration of action of stationary object
If tetracycline antibiotics are formulated for stability, then they can meet shelf life requirements, but they require complex reconstitution procedures, reducing productivity
Solution Approach 1:
The patent creates a composite formulation using semifluorinated alkanes as the vehicle for tetracycline antibiotics. This composite system achieves both long shelf life through enhanced stability and high productivity by eliminating reconstitution steps, allowing direct administration and improving overall administration efficiency.
Data Source
AI summary
Disclosed herein are injectable compositions, such as nonaqueous liquid injectable compositions, comprising at least one tetracycline antibiotic, such as doxycycline, and at least one semifluorinated alkane, such as 1-perfluorohexyloctane (F6H8), as well as methods of treatment or prevention of malar edema, with such compositions. The injectable compositions may further be provided in a container closure system, such as a polypropylene (PP) pre-filled syringe, or in a kit.